Clinical Trials Logo

Chronic Kidney Disease clinical trials

View clinical trials related to Chronic Kidney Disease.

Filter by:

NCT ID: NCT00132431 Completed - Clinical trials for Chronic Kidney Disease

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary hyperparathyroidism (HPT).

NCT ID: NCT00122135 Completed - Lung Cancer Clinical Trials

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

Aim3
Start date: December 2004
Phase: N/A
Study type: Interventional

The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural factors.

NCT ID: NCT00112008 Completed - Clinical trials for Chronic Kidney Disease

Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients not on dialysis. Anemic patients who are not currently receiving ESA therapy will be dosed with darbepoetin alfa Q2W for 18 weeks.

NCT ID: NCT00097747 Completed - Cancer Clinical Trials

Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.

NCT ID: NCT00096915 Completed - Clinical trials for Chronic Kidney Disease

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in CKD patients on dialysis. Anemic patients on hemo and peritoneal dialysis who have achieved and maintained target hemoglobin (Hb) on every other week (Q2W) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (QM) dosing.

NCT ID: NCT00094484 Completed - Clinical trials for Chronic Kidney Disease

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).

NCT ID: NCT00093977 Completed - Clinical trials for Chronic Kidney Disease

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether darbepoetin alfa manufactured by the current "roller bottle" technology and darbepoetin alfa manufactured by a serum free process have a comparable safety profile.

NCT ID: NCT00073710 Completed - Clinical trials for Chronic Kidney Disease

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Start date: September 2004
Phase: Phase 4
Study type: Interventional

A study to investigate the effects of Zemplar and Calcijex on intestinal calcium absorption in hemodialysis subjects.

NCT ID: NCT00064753 Completed - Clinical trials for Cardiovascular Disease

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

FAVORIT
Start date: May 2002
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this randomized clinical trial is to determine if lowering homocysteine levels in renal transplant recipients with a multivitamin will reduce the occurrence of cardiovascular disease outcomes.